AMG 691 / Amgen - LARVOL DELTA

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Amgen | Trial completion date: Oct 2026 ➔ May 2027 | Trial primary completion date: Sep 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Amgen | Trial primary completion date: Mar 2026 ➔ Aug 2026

Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases